Effect of Milnacipran / Gabapentin in Fibromyalgia
Status:
Enrolling by invitation
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and
improvement in the quality of life in fibromyalgia (FM) patients.
Most FM trials focus primarily on pain reduction with monotherapy. Polypharmacy is commonly
used, but supportive evidence is limited.
The gabapentin-MLN combined therapy may be more effective in female patients with FM than
their monotherapy.